# Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

> **NCT03129828** · PHASE1,PHASE2 · COMPLETED · sponsor: **Prof. Dr. Clemens Schmitt** · enrollment: 38 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib and Bortezomib + R-CHOP

## Key facts

- **NCT ID:** NCT03129828
- **Lead sponsor:** Prof. Dr. Clemens Schmitt
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-17
- **Primary completion:** 2024-11-12
- **Final completion:** 2024-11-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-12-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03129828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03129828, "Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03129828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*